TY - JOUR
T1 - Post-Transplant Diabetes Mellitus and Prediabetes in Renal Transplant Recipients
T2 - An Update
AU - Rodríguez-Rodríguez, Ana Elena
AU - Porrini, Esteban
AU - Hornum, Mads
AU - Donate-Correa, Javier
AU - Morales-Febles, Raúl
AU - Khemlani Ramchand, Simran
AU - Molina Lima, María Xixiang
AU - Torres, Armando
N1 - © 2021 S. Karger AG, Basel.
PY - 2021
Y1 - 2021
N2 - Post-transplant diabetes mellitus (PTDM) is a frequent and relevant complication after renal transplantation: it affects 20-30% of renal transplant recipients and increases the risk for cardiovascular and infectious events. Thus, understanding pathogenesis of PTDM would help limiting its consequences. In this review, we analyse novel aspects of PTDM, based on studies of the last decade, such as the clinical evolution of PTDM, early and late, the reversibility rate, diagnostic criteria, risk factors, including pre-transplant metabolic syndrome and insulin resistance (IR) and the interaction between these factors and immunosuppressive medications. Also, we discuss novel pathogenic factors, in particular the role of β-cell function in an environment of IR and common pathways between pre-existing cell damage and tacrolimus-induced toxicity. The relevant role of prediabetes in the pathogenesis of PTDM and cardiovascular disease is also addressed. Finally, current evidence on PTDM treatment is discussed.
AB - Post-transplant diabetes mellitus (PTDM) is a frequent and relevant complication after renal transplantation: it affects 20-30% of renal transplant recipients and increases the risk for cardiovascular and infectious events. Thus, understanding pathogenesis of PTDM would help limiting its consequences. In this review, we analyse novel aspects of PTDM, based on studies of the last decade, such as the clinical evolution of PTDM, early and late, the reversibility rate, diagnostic criteria, risk factors, including pre-transplant metabolic syndrome and insulin resistance (IR) and the interaction between these factors and immunosuppressive medications. Also, we discuss novel pathogenic factors, in particular the role of β-cell function in an environment of IR and common pathways between pre-existing cell damage and tacrolimus-induced toxicity. The relevant role of prediabetes in the pathogenesis of PTDM and cardiovascular disease is also addressed. Finally, current evidence on PTDM treatment is discussed.
KW - Diabetes Mellitus/etiology
KW - Humans
KW - Insulin Resistance
KW - Kidney Transplantation
KW - Prediabetic State/etiology
KW - Transplant Recipients
UR - http://www.scopus.com/inward/record.url?scp=85105126325&partnerID=8YFLogxK
U2 - 10.1159/000514288
DO - 10.1159/000514288
M3 - Review
C2 - 33902027
SN - 0028-2766
VL - 145
SP - 317
EP - 329
JO - Nephron
JF - Nephron
IS - 4
ER -